ALIM Alimera Sciences Inc.

0.92
0  0%
Previous Close 0.92
Open 0.93
Price To Book -2.19
Market Cap 65,320,455
Shares 71,000,495
Volume 82,498
Short Ratio
Av. Daily Volume 88,392

NewsSee all news

  1. Did Changing Sentiment Drive Alimera Sciences's (NASDAQ:ALIM) Share Price Down A Painful 85%?
  2. Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis
  3. Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment
  4. Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
  5. Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. Did Changing Sentiment Drive Alimera Sciences's (NASDAQ:ALIM) Share Price Down A Painful 85%?
  2. Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis
  3. Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment
  4. Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
  5. Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®
  6. Top Ranked Momentum Stocks to Buy for May 21st
  7. Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
  8. Edited Transcript of ALIM earnings conference call or presentation 30-Apr-19 1:00pm GMT
  9. Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview
  10. Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update
  11. Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting
  12. Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer
  13. Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe
  14. Alimera Sciences Announces Approval for ILUVIEN (R) in Kuwait
  15. Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France
  16. Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT
  17. Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know
  18. Alimera Sciences, Inc. to Host Earnings Call
  19. Alimera Sciences Reports Record Fourth Quarter and 2018 Results
  20. Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon